SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) is the largest cardiovascular outcome trial of a GLP-1 receptor agonist in adults without diabetes. Results led to the first FDA approval of a weight-management drug for a cardiovascular outcome.

Trial design

SELECT (Lincoff et al., NEJM 2023) enrolled 17,604 adults with BMI ≥27 and established CVD, without diabetes. Randomized to semaglutide 2.4 mg weekly or placebo, on top of standard CV care.

Results

EndpointSemaglutidePlaceboEffect
MACE (3-point)6.5%8.0%20% relative reduction (HR 0.80, p<0.001)
CV death2.5%3.0%HR 0.85
Non-fatal MI2.7%3.7%HR 0.72
Non-fatal stroke1.7%1.9%HR 0.93
Weight at 52 wk−9.4%−0.9%−8.5% difference

Median follow-up 39.8 months. MACE benefit emerged early (within 6 months) and persisted.

Mechanism beyond weight loss

The CV benefit appears larger than would be predicted from weight loss alone. Proposed mechanisms: direct GLP-1 effects in vascular endothelium and myocardium, reduced systemic inflammation, improved insulin sensitivity, blood pressure reduction.

Regulatory and coverage implications

What "established CVD" means

SELECT enrolled patients with any of: prior MI, prior ischemic or hemorrhagic stroke, or symptomatic PAD. Patients with diabetes were excluded.

What we don't yet know

See our detailed cardiovascular conditions page.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.